ARTICLE
1 October 2018

Congress Agrees To Final Opioids Bill With Vote Scheduled This Week

B
BakerHostetler

Contributor

BakerHostetler logo
Recognized as one of the top firms for client service, BakerHostetler is a leading national law firm that helps clients around the world address their most complex and critical business and regulatory issues. With five core national practice groups — Business, Labor and Employment, Intellectual Property, Litigation, and Tax — the firm has more than 970 lawyers located in 14 offices coast to coast. BakerHostetler is widely regarded as having one of the country’s top 10 tax practices, a nationally recognized litigation practice, an award-winning data privacy practice and an industry-leading business practice. The firm is also recognized internationally for its groundbreaking work recovering more than $13 billion in the Madoff Recovery Initiative, representing the SIPA Trustee for the liquidation of Bernard L. Madoff Investment Securities LLC. Visit bakerlaw.com
House and Senate leaders Wednesday agreed to sweeping new legislation to respond to the national opioid epidemic.
United States Criminal Law
To print this article, all you need is to be registered or login on Mondaq.com.

House and Senate leaders Wednesday agreed to sweeping new legislation to respond to the national opioid epidemic, including authorizing $8 billion in grant programs for states, expanding access to prevention and treatment, and cracking down on illicit drug shipments in the mail.

A section-by-section analysis of the legislation can be found here.

The House is scheduled to vote on the bill this week before adjourning for the midterm elections. The Senate is expected to vote early next month, sending the bill to the White House, where aides say President Donald Trump is expected to sign it into law.

Among the provisions dropped from the final legislation were changes to privacy rules that would have allowed substance abuse treatment records to be shared more widely among providers. Also not included was an unrelated change to drug discounts that pharmaceutical manufacturers provide in the Medicare Part D coverage gap.

Related Ohio Clock blog coverage of the opioids bill can be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More